This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

About PREVYMIS® (letermovir)

Updated on 28/05/2019

HAEMATOLOGY

A novel therapy for CMV (cytomegalovirus) prophylaxis

Indication: PREVYMIS is indicated for prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT).1

PREVYMIS is the first and only CMV DNA terminase inhibitor, providing patients with a path of protection from the start of their haematopoietic stem cell transplant.1

With its novel mechanism of action, PREVMYIS targets a component of the terminase complex involved in viral DNA cleavage and packaging, which restricts drug activity to the virus alone.1 Cross-resistance is therefore not likely with agents with a different mechanism of action.1

Any level of CMV is associated with an increased risk of mortality in the first year post-allogeneic HSCT2

PREVYMIS has demonstrated –

  • Superior efficacy in CMV prophylaxis at week 24 compared to placebo1
  • Lower all-cause mortality vs placebo post-transplant3
  • A generally well tolerated safety profile1
  • Once-daily oral dosing – as early as day 0 and through day 1001

Start PREVYMIS as early as day 0 in adult CMV-seropositive (R+) allogeneic HSCT patients1

(Not an actual patient.)

What is PREVYMIS (letermovir), and how may it benefit your adult allogeneic HSCT recipients?

Prescribing Information

Length: 08:51

Professor Karl Peggs, Consultant Haematologist, University College London Hospitals NHS Foundation Trust.

Letermovir is a novel drug licensed for the prevention of cytomegalovirus (CMV) reactivation following allogeneic haematopoietic stem cell transplantation. Here, Professor Peggs introduces letermovir and discusses the trial data including its mechanism of action, efficacy, safety and toxicity profile. The introduction of this prophylaxis and its implications for clinical practice is also discussed.

Related content

 

References

  1. PREVYMIS Summary of Product Characteristics.
  2. Green ML, Leisenring W, Xie H, et al. Cytomegalovirus viral load and mortality after haematopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol. 2016;3:e119-e127.
  3. Marty FM, Ljungman P, Chemaly RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377:2433–2444.

Supporting documentation

Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

GB-CYT-00015 | Date of Preparation: May 2019